Search results
Results From The WOW.Com Content Network
According to the Journal Citation Reports, its 2014 impact factor is 2.600, ranking it 25 out of 86 journals in the category "Health Care Sciences & Services" [1] and 12 out of 70 journals in the category "Health Policy & Services". [2]
According to the Journal Citation Reports, the journal has a 2021 impact factor of 20.693, ranking it 2nd out of 37 journals in the "Virology" category. [4]
The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Impact factors began to be calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, [4] and became known as Thomson ISI.
The Emerging Sources Citation Index (ESCI) is a citation index produced since 2015 by Thomson Reuters and now by Clarivate. According to the publisher, the index includes "peer-reviewed publications of regional importance and in emerging scientific fields". [1] The ESCI is accessible through the Web of Science, together with other Clarivate ...
It provides information about academic journals in the natural and social sciences, including impact factors. JCR was originally published as a part of the Science Citation Index. Currently, the JCR, as a distinct service, is based on citations compiled from the Science Citation Index Expanded and the Social Sciences Citation Index. [2]
Indexed by ISI Cancer Epidemiology, Biomarkers & Prevention collected an impact factor of 5.057 as reported in the 2018 Journal Citation Reports by Thomson Reuters, ranking it 48 out of 230 journals in the category Oncology [2] and ranking it 13 out of 186 journals in the category Public, environmental & occupational health. [3]
Clarivate [6] was formerly the Intellectual Property and Science division of Thomson Reuters.Before 2008, it was known as Thomson Scientific. [7] In 2016, Thomson Reuters struck a $3.55 billion deal in which they spun it off as an independent company, and sold it to private-equity firms Onex Corporation and Baring Private Equity Asia.
According to the Journal Citation Reports, the journal had a 2022 impact factor of 12.8. In 2020, it ranked at the 14th out of 140 journals in the category "Medicine, Research & Experimental" and 34th out of 298 journals in the category "Biochemistry & Molecular Biology". [5]